# Synthesis of Some New Thiazole Derivatives and Their Biological Activity Evaluation

Authors: Leyla Yurttaş; Yusuf Özkay; Hülya Karaca Gençer; Ulviye Acar
Journal: Journal of Chemistry
 (2015)

---

## Abstract

New 2-(4-arylpiperazine-1-yl)-N-[4-(2-(4-substituted phenyl)thiazol-4-yl)phenyl]acetamide derivatives were synthesized and evaluated for their antimicrobial and anticholinesterase activities. Acetylcholinesterase inhibitory activities of the compounds were found weak contrary to expectations. It is unlikely that antifungal activity of the compounds was found significant, especially against Candida parapsilosis.


---

## Body

## 1. Introduction

The treatment of infectious diseases still remains a challenging task because of combination of factors including increasing number of multidrug resistant, microbial pathogens and emerging newer infectious diseases [1]. The therapeutic problem is a crucial part of hospitalized patients, immunosuppressed patients with AIDS, and those undergoing anticancer therapy or organ transplants. In spite of a large number of antibiotics and chemotherapeutics available for medical use, the emerging resistance to old and antibiotics has created a substantial need for novel classes of antimicrobial agents [2]. So, it is necessary to design new and effective molecules as antimicrobial agents.Small-ring heterocycles including nitrogen and sulfur have been under investigation for a long time on account of their synthetic diversity and therapeutic relevance. Among the wide range of heterocycles explored to privileged candidates in drug discovery, thiazoles have been identified to play a necessary role in medical chemistry [3].Thiazole ring is a structural fragment of natural compounds such as thiamine (vitamin B1), thiamine pyrophosphate (TPP, a coenzyme important in respiration in the Krebs cycle), epothilones, carboxylase, and the large family of macrocyclic thiopeptide antibiotics, thiostrepton and micrococcin P1 [4, 5]. Thiazole derivatives are associated with a broad spectrum of biological properties, including anticonvulsant, antimicrobial, antituberculous, bacteriostatic activities, antiviral, antimalarial, anticancer, hypertension, inflammation, schizophrenia, HIV infections, hypnotics and more recently for the treatment of pain, as fibrinojen receptor antagonists with antithrombotic activity, as new inhibitors of bacterial DNA gyrase B [6–10]. Thiazole derivatives are also found in application in the drug development for the treatment of allergies [11].Many currently notable drugs contain piperazine ring and amide moiety as part of their molecular structure [12]. Piperazines are also among the most important building blocks in today’s drug discovery and are found in biologically active compounds across a number of different therapeutic areas such as antifungal, antibacterial, antimalarial, and antipsychotic activities [13].In our previous study, cholinesterase activity of some thiazole-piperazine derivatives was reported [14]. Prompted from the data we have obtained before and the above literature research, we synthesized a new series of thiazole-piperazine derivatives and investigated their antimicrobial and anticholinesterase activities so as to obtain new biologically active compounds.


## 2. Experimental

### 2.1. Material

Melting points (°C, uncorrected) of the synthesized compounds were determined by using electrothermal melting point apparatus (Electrothermal, Essex, UK).1H NMR spectra were recorded with a Bruker 500 MHz digital FT-NMR spectrometer (Bruker Bioscience, Billerica, MA, USA) and 13C NMR spectra were recorded with a Bruker 125 MHz digital FT-NMR spectrometer in DMSO-d6 solvent including TMS as an internal standard. Coupling constants (J) are reported as Hertz. IR spectra were obtained in KBr pressed pellets via IR, Shimadzu 8400S spectrophotometer (Shimadzu, Tokyo, Japan). Mass spectra of fast atom bombardment (FAB) were obtained on a VG Quattro mass spectrometer VG Quattro Mass spectrometer (Fisons Instruments Vertriebs GmbH, Mainz, Germany). The purities of compounds were checked by TLC on silica gel 60 F254 (Merck KGaA, Darmstadt, Germany). Starting materials were either commercially available or synthesized according to the methods given in the literature.


### 2.2. General Procedure for the Synthesis of 2-(4-Arylpiperazine-1-yl)-N-[4-(2-(4-substituted phenyl)thiazol-4-yl)phenyl]acetamide Derivatives (6a–6p)

A mixture of compound 2-chloro-N-[4-(2-(4-substituted phenyl)-4-thiazolyl)phenyl]acetamide5(1.5 mmol), appropriate piperazine derivative (1.8 mmol) and K2CO3 (1.5 mmol) in acetone, was refluxed for 2 h. After cooling, the solvent was evaporated until dryness. The residue was treated with 25 mL of water. Solidified product was filtered, washed with water, and recrystallized from ethanol to give the compounds6a–6p.


#### 2.2.1.2-(4-Benzylpiperazin-1-yl)-N-[4-(2-phenylthiazol-4-yl)phenyl]acetamide (6a)

Yield 70–76%, m.p. 171–174°C. IR (KBr)νmax (cm−1): 3281 (amide N-H), 3005 (aromatic C-H), 2912 (aliphatic C-H), 1676 (amide C=O), 1512–1306 (C=C and C=N), 1190–978 (C-O and C-N). 1H-NMR (125 MHz, DMSO-d6, ppm): δ 2.45 (4H, t, J=5 Hz, N-CH2), 2.55 (4H, t, J=4.5Hz, N-CH2), 3.15 (2H, s, COCH2), 3.49 (2H, s, C-CH2), 7.25–7.35 (5H, m, Ar-H), 7.51–7.56 (3H, m, Ar-H), 7.75 (2H, d, J=9 Hz, Ar-H), 7.99-8.04 (4H, m, Ar-H), 8.09 (1H, s, Ar-H), 9.82 (1H, s, N-H). 13C-NMR (500 MHz, DMSO-d6, ppm): δ 52.45, 52.80, 61.81, 62.04, 113.44, 119.49, 126.17, 126.53, 126.87, 128.14, 128.79, 129.17, 129.25, 130.32, 133.01, 138.22, 138.58, 154.96, 166.81, 168.35. For C28H28N4OS calculated: (%) C 71.76, H 6.02, N 11.96; found: (%) C 71.71, H 6.10, N 11.91. MS: m/z 469 (M + 1).


#### 2.2.2. 2-[4-(Pyridin-2-yl)piperazin-1-yl]-N-[4-(2-phenylthiazol-4-yl)phenyl]acetamide (6b)

Yield 70–76 %, m.p. 173–176°C. IR (KBr)νmax (cm−1): 3319 (amide N-H), 3091 (aromatic C-H), 2912 (aliphatic C-H), 1676 (amide C=O), 1524–1309 (C=C and C=N), 1246–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.61 (4H, t, J=5 Hz, N-CH2), 3.23 (2H, s, COCH2), 3.76 (4H, brs, N-CH2), 6.63-6.64 (1H, m, Ar-H), 6.99-7.00 (1H, m, Ar-H), 7.52–7.56 (4H, m, Ar-H), 7.76 (2H, d, J=9 Hz, Ar-H), 7.84–7.85 (1H, m, Ar-H), 8.00–8.09 (5H, m, Ar-H), 9.92 (1H, s, N-H). For C26H25N5OS calculated: (%) C 68.55, H 5.53, N 15.37; found: (%) C 68.62, H 5.63, N 15.40. MS: m/z 456 (M + 1).


#### 2.2.3. 2-[4-(Pyrimidin-2-yl)piperazin-1-yl]-N-[4-(2-phenylthiazol-4-yl)phenyl]acetamide (6c)

Yield 75–78 %, m.p. 210–216°C. IR (KBr)νmax (cm−1): 3253 (amide N-H), 3053 (aromatic C-H), 2987 (aliphatic C-H), 1674 (amide C=O), 1585–1309 (C=C and C=N), 1228–979 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.59 (4H, t, J=5 Hz, N-CH2), 3.21 (2H, s, COCH2), 3.82 (4H, t, J=4.5 Hz, N-CH2), 6.62 (1H, t, J=4.5 Hz, Ar-H), 7.38 (2H, t, J=7.5 Hz, Ar-H), 7.77 (2H, d, J=8 Hz, Ar-H), 8.00 (2H, d, J=8 Hz, Ar-H), 8.06–8.08 (4H, m, Ar-H), 8.35 (2H, d, J=4.5 Hz, Ar-H), 9.93 (1H, s, N-H). 13C-NMR (125 MHz, DMSO-d6, ppm): δ 43.22, 52.48, 61.71, 110.08, 113.44, 119.57, 126.17, 126.52, 129.20, 129.24, 130.31, 133.02, 138.62, 154.97, 157.89, 161.20, 166.80, 168.28. For C25H24N6OS calculated: (%) C 65.77, H 5.30, N 18.41; found: (%) C 65.67, H 5.33, N 18.36. MS: m/z 457 (M + 1).


#### 2.2.4. 2-[4-(2-Furoyl)piperazin-1-yl]-N-[4-(2-phenylthiazol-4-yl)phenyl]acetamide (6d)

Yield 70–72%, m.p. 144-145°C. IR (KBr)νmax (cm−1): 3215 (amide N-H), 3034 (aromatic C-H), 2975 (aliphatic C-H), 1676 (amide C=O), 1625–1308 (C=C and C=N), 1263–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.62 (4H, t, J=4.5 Hz, N-CH2), 3.22 (2H, s, COCH2), 3.75 (4H, t, J=4.5 Hz, N-CH2), 6.62-6.63 (1H, m, Ar-H), 7.03 (1H, d, J=3.5 Hz, Ar-H), 7.08 (2H, d, J=8.5 Hz, Ar-H), 7.79 (3H, m, Ar-H), 7.87 (1H, s, Ar-H), 7.97–8.05 (5H, m, Ar-H), 9.93 (1H, s, N-H). For C26H24N4O3S calculated: (%) C 66.08, H 5.12, N 11.86; found: (%) C 68.13, H 5.17, N 11.93. MS: m/z 473 (M + 1).


#### 2.2.5. 2-(4-Benzylpiperazin-1-yl)-N-[4-(2-(4-methoxyphenyl)thiazol-4-yl)phenyl]acetamide (6e)

Yield 80–82%, m.p. 171–175°C. IR (KBr)νmax (cm−1): 3302 (amide N-H), 3041 (aromatic C-H), 2952 (aliphatic C-H), 1653 (amide C=O), 1587–1305 (C=C and C=N), 1244–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.46 (4H, t, J=5 Hz, N-CH2), 2.56 (4H, t, J=4.5 Hz, N-CH2), 3.14 (2H, s, COCH2), 3.48 (2H, s, C-CH2), 3.83 (3H, s, OCH3), 7.08 (2H, d, J=9 Hz, Ar-H), 7.30–7.32 (5H, m, Ar-H), 7.72 (2H, d, J=8.5 Hz, Ar-H), 7.95–7.98 (5H, m, Ar-H), 9.82 (1H, s, N-H). For C29H30N4O2S calculated: (%) C 69.85, H 6.06, N 11.24; found: (%) C 69.92, H 6.14, N 11.31. MS: m/z 499 (M + 1).


#### 2.2.6. 2-[4-(Pyridin-2-yl)piperazin-1-yl]-N-[4-(2-(4-methoxyphenyl)thiazol-4-yl)phenyl]acetamide (6f)

Yield 78–80%, m.p. 153-154°C. IR (KBr)νmax (cm−1): 3317 (amide N-H), 3014 (aromatic C-H), 2941 (aliphatic C-H), 1656 (amide C=O), 1589–1303 (C=C and C=N), 1247–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.63 (4H, t, J=5 Hz, N-CH2), 3.21 (2H, s, COCH2), 3.56 (4H, t, J=4.5 Hz, N-CH2), 3.84 (3H, s, OCH3), 6.63 (1H, t, J=6 Hz, Ar-H), 6.83 (1H, d, J=8.5 Hz, Ar-H), 7.08 (2H, d, J=9 Hz, Ar-H), 7.52 (1H, t, J=5 Hz, Ar-H), 7.76 (2H, d, J=8.5 Hz, Ar-H), 7.95–7.99 (5H, m, Ar-H), 8.11 (1H, d, J=5 Hz, Ar-H), 9.90 (1H, s, N-H). For C27H27N5O2S calculated: (%) C 66.78, H 5.60, N 14.42; found: (%) C 66.85, H 5.68, N 14.50. MS: m/z 486 (M + 1).


#### 2.2.7. 2-[4-(Pyrimidin-2-yl)piperazin-1-yl]-N-[4-(2-(4-methoxyphenyl)thiazol-4-yl)phenyl]acetamide (6g)

Yield 78–80%, m.p. 160–163°C. IR (KBr)νmax (cm−1): 3315 (amide N-H), 3038 (aromatic C-H), 2951 (aliphatic C-H), 1676 (amide C=O), 1596–1307 (C=C and C=N), 1261–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.59 (4H, t, J=5 Hz, N-CH2), 3.21 (2H, s, COCH2), 3.81 (4H, t, J=5 Hz, N-CH2), 3.83 (3H, s, OCH3), 6.63 (1H, t, J=4.5 Hz, Ar-H), 7.08 (2H, d, J=9 Hz, Ar-H), 7.76 (2H, d, J=9 Hz, Ar-H), 7.95-7.96 (5H, m, Ar-H), 8.36 (2H, d, J=5 Hz, Ar-H), 9.91 (1H, s, N-H). For C26H26N6O2S calculated: (%) C 64.18, H 5.39, N 17.27; found: (%) C 64.25, H 5.44, N 17.32. MS: m/z 487 (M + 1).


#### 2.2.8. 2-[4-(2-Furoyl)piperazin-1-yl]-N-[4-(2-(4-methoxyphenyl)thiazol-4-yl)phenyl]acetamide (6h)

Yield 74–76%, m.p. 136–138°C. IR (KBr)νmax (cm−1): 3279 (amide N-H), 3063 (aromatic C-H), 2927 (aliphatic C-H), 1658 (amide C=O), 1604–1306 (C=C and C=N), 1236–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.61 (4H, t, J=5 Hz, N-CH2), 3.24 (2H, s, COCH2), 3.76 (4H, t, J=5 Hz, N-CH2), 3.87 (3H, s, OCH3), 6.63-6.64 (1H, m, Ar-H), 7.01 (1H, d, J=3.5 Hz, Ar-H), 7.08 (2H, d, J=9 Hz, Ar-H), 7.77 (2H, d, J=8.5 Hz, Ar-H), 7.85 (1H, s, Ar-H), 7.96–8.01 (5H, m, Ar-H), 9.94 (1H, s, N-H). 13C-NMR (125 MHz, DMSO-d6, ppm): δ 53.18, 53.55, 55.87, 61.82, 111.76, 112.85, 115.06, 115.40, 115.99, 120.08, 126.37, 126.96, 128.25, 129.84, 139.00, 145.15, 147.48, 155.17, 158.79, 161.41, 167.21, 168.66. For C27H26N4O4S calculated: (%) C 64.52, H 5.21, N 11.15; found: (%) C 64.46, H 5.29, N 11.24. MS: m/z 503 (M + 1).


#### 2.2.9. 2-(4-Benzylpiperazin-1-yl)-N-[4-(2-(4-chlorophenyl)thiazol-4-yl)phenyl]acetamide (6i)

Yield 70–73%, m.p. 171–173°C. IR (KBr)νmax (cm−1): 3288 (amide N-H), 3013 (aromatic C-H), 2966 (aliphatic C-H), 1664 (amide C=O), 1591–1315 (C=C and C=N), 1234–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.50 (4H, brs, N-CH2), 3.14 (2H, s, COCH2), 3.48 (2H, s, C-CH2), 7.08 (2H, d, J=9 Hz, Ar-H), 7.29–7.32 (5H, m, Ar-H), 7.60 (2H, d, J=8.5 Hz, Ar-H), 7.75 (2H, d, J=8.5 Hz, Ar-H), 7.97 (1H, d, J=8.5 Hz, Ar-H), 8.04 (1H, d, J=8.5 Hz, Ar-H), 8.11 (1H, s, Ar-H), 9.82 (1H, s, N-H). For C28H27ClN4OS calculated: (%) C 66.85, H 5.41, N 11.14; found: (%) C 66.94, H 5.47, N 11.20. MS: m/z 502.5 (M + 1).


#### 2.2.10. 2-[4-(Pyridin-2-yl)piperazin-1-yl]-N-[4-(2-(4-chlorophenyl)thiazol-4-yl)phenyl]acetamide (6j)

Yield 73–76%, m.p. 220–225°C. IR (KBr)νmax (cm−1): 3300 (amide N-H), 3002 (aromatic C-H), 2924 (aliphatic C-H), 1666 (amide C=O), 1591–1305 (C=C and C=N), 1244–1018 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.63 (4H, t, J=4.5 Hz, N-CH2), 3.22 (2H, s, COCH2), 3.56 (4H, t, J=4.5 Hz, N-CH2), 6.63–6.65 (1H, m, Ar-H), 6.83 (1H, d, J=8.5 Hz, Ar-H), 7.53 (1H, t, J=4.5 Hz, Ar-H), 7.60 (2H, d, J=8.5 Hz, Ar-H), 7.78 (2H, d, J=8.5 Hz, Ar-H), 8.03 (2H, d, J=8.5 Hz, Ar-H), 8.06 (2H, d, J=8.5 Hz, Ar-H), 8.12 (2H, s, Ar-H), 9.92 (1H, s, N-H). 13C-NMR (125 MHz, DMSO-d6, ppm): δ 45.05, 52.98, 62.25, 107.58, 113.45, 114.44, 120.06, 127.05, 128.37, 129.53, 129.81, 132.34, 135.33, 137.98, 139.19, 148.04, 155.60, 159.51, 165.95, 168.80. For C26H24ClN5OS calculated: (%) C 63.73, H 4.94, N 14.29; found: (%) C 63.81, H 4.98, N 14.32. MS: m/z 489.5 (M + 1).


#### 2.2.11. 2-[4-(Pyrimidin-2-yl)piperazin-1-yl]-N-[4-(2-(4-chlorophenyl)thiazol-4-yl)phenyl]acetamide (6k)

Yield 70–74%, m.p. 196–198°C. IR (KBr)νmax (cm−1): 3290 (amide N-H), 3022 (aromatic C-H), 2931 (aliphatic C-H), 1670 (amide C=O), 1585–1309 (C=C and C=N), 1256–979 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.59 (4H, t, J=4.5 Hz, N-CH2), 3.21 (2H, s, COCH2), 3.81 (4H, t, J=4.5 Hz, N-CH2), 6.62 (1H, t, J=5 Hz, Ar-H), 7.59 (2H, d, J=8.5 Hz, Ar-H), 7.77 (2H, d, J=8.5 Hz, Ar-H), 8.02 (2H, d, J=8.5 Hz, Ar-H), 8.05 (2H, d, J=8.5 Hz, Ar-H), 8.12 (1H, s, Ar-H), 8.35 (2H, d, J=4.5 Hz, Ar-H), 9.92 (1H, s, N-H). For C25H23ClN6OS calculated: (%) C 61.15, H 4.72, N 17.12; found: (%) C 61.23, H 4.80, N 17.16. MS: m/z 490.5 (M + 1).


#### 2.2.12. 2-[4-(2-Furoyl)piperazin-1-yl]-N-[4-(2-(4-chlorophenyl)thiazol-4-yl)phenyl]acetamide (6l)

Yield 72–75%, m.p. 139–141°C. IR (KBr)νmax (cm−1): 3317 (amide N-H), 3042 (aromatic C-H), 2962 (aliphatic C-H), 1676 (amide C=O), 1625–1305 (C=C and C=N), 1261–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.60 (4H, t, J=5 Hz, N-CH2), 3.34 (2H, s, COCH2), 3.74 (4H, t, J=5 Hz, N-CH2), 6.62-6.63 (1H, m, Ar-H), 7.01 (1H, d, J=3.5 Hz, Ar-H), 7.59 (2H, d, J=8.5 Hz, Ar-H), 7.76–7.83 (2H, m, Ar-H), 7.95–8.15 (6H, s, Ar-H), 9.96 (1H, s, N-H). For C26H23ClN4O3S calculated: (%) C 61.59, H 4.57, N 11.05; found: (%) C 61.65, H 4.63, N 11.12. MS: m/z 506.5 (M + 1).


#### 2.2.13. 2-(4-Benzylpiperazin-1-yl)-N-[4-(2-(4-florophenyl)thiazol-4-yl)phenyl]acetamide (6m)

Yield 69–73%, m.p. 171-172°C. IR (KBr)νmax (cm−1): 3317 (amide N-H), 3015 (aromatic C-H), 2970 (aliphatic C-H), 1678 (amide C=O), 1502–1306 (C=C and C=N), 1234–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.45 (4H, t, J=5 Hz, N-CH2), 2.54 (4H, t, J=4.5 Hz, N-CH2), 3.14 (2H, s, COCH2), 3.48 (2H, s, C-CH2), 7.24–7.39 (7H, m, Ar-H), 7.73 (2H, d, J=8.5 Hz, Ar-H), 7.99 (2H, d, J=8.5 Hz, Ar-H), 8.06–8.11 (3H, m, Ar-H), 9.85 (1H, s, N-H). For C28H27FN4OS calculated: (%) C 69.11, H 5.59, N 11.51; found: (%) C 69.18, H 5.65, N 11.63. MS: m/z 487 (M + 1).


#### 2.2.14. 2-[4-(Pyridin-2-yl)piperazin-1-yl]-N-[4-(2-(4-florophenyl)thiazol-4-yl)phenyl]acetamide (6n)

Yield 70–74%, m.p. 163-164°C. IR (KBr)νmax (cm−1): 3317 (amide N-H), 3023 (aromatic C-H), 2987 (aliphatic C-H), 1678 (amide C=O), 1591–1305 (C=C and C=N), 1247–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.63 (4H, t, J=4.5 Hz, N-CH2), 3.22 (2H, s, COCH2), 3.56 (4H, t, J=5 Hz, N-CH2), 6.62–6.65 (1H, m, Ar-H), 6.83 (1H, d, J=8.5 Hz, Ar-H), 7.35–7.39 (2H, m, Ar-H), 7.53 (1H, t, J=4.5 Hz, Ar-H), 7.76 (2H, d, J=8.5 Hz, Ar-H), 7.99 (2H, d, J=8.5 Hz, Ar-H), 8.06–8.12 (4H, m, Ar-H), 9.91 (1H, s, N-H). For C26H24FN5OS calculated: (%) C 65.94, H 5.11, N 14.79; found: (%) C 65.86, H 5.18, N 14.65. MS: m/z 474 (M + 1).


#### 2.2.15. 2-[4-(Pyrimidin-2-yl)piperazin-1-yl]-N-[4-(2-(4-florophenyl)thiazol-4-yl)phenyl]acetamide (6o)

Yield 70–74%, m.p. 187-188°C. IR (KBr)νmax (cm−1): 3317 (amide N-H), 3036 (aromatic C-H), 2954 (aliphatic C-H), 1677 (amide C=O), 1583-1307 (C=C and C=N), 1257–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.61 (4H, t, J=3 Hz, N-CH2), 3.22 (2H, s, COCH2), 3.83 (4H, t, J=4.5 Hz, N-CH2), 6.63 (1H, t, J=4.5 Hz, Ar-H), 7.50–7.56 (3H, m, Ar-H), 7.78 (2H, d, J=9 Hz, Ar-H), 7.98–8.06 (4H, m, Ar-H), 8.09 (1H, s, Ar-H), 8.37 (2H, d, J=8.5 Hz, Ar-H), 9.93 (1H, s, N-H). 13C-NMR (125 MHz, DMSO-d6, ppm): δ 43.71, 52.97, 62.19, 110.59, 114.03, 116.68, 116.85, 120.07, 127.02, 128.95, 129.02, 129.62, 130.19, 139.14, 155.44, 158.40, 161.70, 162.74, 166.13, 168.80. For C25H23FN6OS calculated: (%) C 63.27, H 4.89, N 17.71; found: (%) C 63.19, H 4.94, N 17.66. MS: m/z 475 (M + 1).


#### 2.2.16. 2-[4-(2-Furoyl)piperazin-1-yl]-N-[4-(2-(4-florophenyl)thiazol-4-yl)phenyl]acetamide (6p)

Yield 74–78%, m.p. 146–148°C. IR (KBr)νmax (cm−1): 3319 (amide N-H), 3031 (aromatic C-H), 2927 (aliphatic C-H), 1674 (amide C=O), 1589–1307 (C=C and C=N), 1232–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.60 (4H, t, J=5 Hz, N-CH2), 3.34 (2H, s, COCH2), 3.74 (4H, t, J=5 Hz, N-CH2), 6.61–6.62 (1H, m, Ar-H), 7.03 (1H, d, J=3.5 Hz, Ar-H), 7.61 (2H, d, J=8.5 Hz, Ar-H), 7.75–7.80 (2H, m, Ar-H), 7.98–8.16 (6H, s, Ar-H), 9.92 (1H, s, N-H). For C26H23FN4O3S calculated: (%) C 63.66, H 4.73, N 11.42; found: (%) C 63.72, H 4.81, N 11.46. MS: m/z 491 (M + 1).


### 2.3. Antimicrobial Activity

The study was designed to compare MICs obtained by the CLSI reference M7–A7 broth microdilution method [15]. MIC readings were performed twice for each chemical agent. Final products were tested for theirin vitro growth inhibitory activity against human pathogenic microorganisms as Gram-positive bacteria,Enterococcus faecalis (ATCC 29212) and as Gram-negative bacteria,Pseudomonas aeruginosa (ATCC 27853),Klebsiella pneumoniae (ATCC 700603),Escherichia coli (ATCC 35218), andE. coli (ATCC 25922) and yeast asCandida albicans(90028),Candida glabrata (ATCC 90030),Candida krusei (ATCC 6258), andCandida parapsilosis (ATCC 7330). Chloramphenicol and ketoconazole were used as control drugs.


### 2.4. Anticholinesterase Activity

The inhibition of acetylcholinesterase enzyme, AChE (E.C.3.1.1.7 from Electric Eel, 500 units), was determined spectrophotometrically using acetylthiocholine (ATC) as substrate according to the modified method of Ellman’s test [16]. Enzyme solutions were prepared in gelatin solution (1%), at a concentration of 2.5 units/mL. AChE and compound solution (50 µL) which is prepared in 2% dimethyl sulfoxide at 0.1 and 1 mM concentrations were added to 3.0 mL phosphate buffer (pH 8 ± 0.1) and incubated at 25°C for 5 min. The reaction was started by adding 5,5-dithio-bis(2-nitrobenzoic)acid, DTNB (50 µL), and ATC (10 µL) to the enzyme-inhibitor mixture. Spectrophotometric measurements were performed on a 1700 Shimadzu UV-1700 UV–Vis spectrophotometer at 412 nm. Donepezil hydrochloride was used as a positive control and all processes were assayed in triplicate [17].


## 2.1. Material

Melting points (°C, uncorrected) of the synthesized compounds were determined by using electrothermal melting point apparatus (Electrothermal, Essex, UK).1H NMR spectra were recorded with a Bruker 500 MHz digital FT-NMR spectrometer (Bruker Bioscience, Billerica, MA, USA) and 13C NMR spectra were recorded with a Bruker 125 MHz digital FT-NMR spectrometer in DMSO-d6 solvent including TMS as an internal standard. Coupling constants (J) are reported as Hertz. IR spectra were obtained in KBr pressed pellets via IR, Shimadzu 8400S spectrophotometer (Shimadzu, Tokyo, Japan). Mass spectra of fast atom bombardment (FAB) were obtained on a VG Quattro mass spectrometer VG Quattro Mass spectrometer (Fisons Instruments Vertriebs GmbH, Mainz, Germany). The purities of compounds were checked by TLC on silica gel 60 F254 (Merck KGaA, Darmstadt, Germany). Starting materials were either commercially available or synthesized according to the methods given in the literature.


## 2.2. General Procedure for the Synthesis of 2-(4-Arylpiperazine-1-yl)-N-[4-(2-(4-substituted phenyl)thiazol-4-yl)phenyl]acetamide Derivatives (6a–6p)

A mixture of compound 2-chloro-N-[4-(2-(4-substituted phenyl)-4-thiazolyl)phenyl]acetamide5(1.5 mmol), appropriate piperazine derivative (1.8 mmol) and K2CO3 (1.5 mmol) in acetone, was refluxed for 2 h. After cooling, the solvent was evaporated until dryness. The residue was treated with 25 mL of water. Solidified product was filtered, washed with water, and recrystallized from ethanol to give the compounds6a–6p.


### 2.2.1.2-(4-Benzylpiperazin-1-yl)-N-[4-(2-phenylthiazol-4-yl)phenyl]acetamide (6a)

Yield 70–76%, m.p. 171–174°C. IR (KBr)νmax (cm−1): 3281 (amide N-H), 3005 (aromatic C-H), 2912 (aliphatic C-H), 1676 (amide C=O), 1512–1306 (C=C and C=N), 1190–978 (C-O and C-N). 1H-NMR (125 MHz, DMSO-d6, ppm): δ 2.45 (4H, t, J=5 Hz, N-CH2), 2.55 (4H, t, J=4.5Hz, N-CH2), 3.15 (2H, s, COCH2), 3.49 (2H, s, C-CH2), 7.25–7.35 (5H, m, Ar-H), 7.51–7.56 (3H, m, Ar-H), 7.75 (2H, d, J=9 Hz, Ar-H), 7.99-8.04 (4H, m, Ar-H), 8.09 (1H, s, Ar-H), 9.82 (1H, s, N-H). 13C-NMR (500 MHz, DMSO-d6, ppm): δ 52.45, 52.80, 61.81, 62.04, 113.44, 119.49, 126.17, 126.53, 126.87, 128.14, 128.79, 129.17, 129.25, 130.32, 133.01, 138.22, 138.58, 154.96, 166.81, 168.35. For C28H28N4OS calculated: (%) C 71.76, H 6.02, N 11.96; found: (%) C 71.71, H 6.10, N 11.91. MS: m/z 469 (M + 1).


### 2.2.2. 2-[4-(Pyridin-2-yl)piperazin-1-yl]-N-[4-(2-phenylthiazol-4-yl)phenyl]acetamide (6b)

Yield 70–76 %, m.p. 173–176°C. IR (KBr)νmax (cm−1): 3319 (amide N-H), 3091 (aromatic C-H), 2912 (aliphatic C-H), 1676 (amide C=O), 1524–1309 (C=C and C=N), 1246–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.61 (4H, t, J=5 Hz, N-CH2), 3.23 (2H, s, COCH2), 3.76 (4H, brs, N-CH2), 6.63-6.64 (1H, m, Ar-H), 6.99-7.00 (1H, m, Ar-H), 7.52–7.56 (4H, m, Ar-H), 7.76 (2H, d, J=9 Hz, Ar-H), 7.84–7.85 (1H, m, Ar-H), 8.00–8.09 (5H, m, Ar-H), 9.92 (1H, s, N-H). For C26H25N5OS calculated: (%) C 68.55, H 5.53, N 15.37; found: (%) C 68.62, H 5.63, N 15.40. MS: m/z 456 (M + 1).


### 2.2.3. 2-[4-(Pyrimidin-2-yl)piperazin-1-yl]-N-[4-(2-phenylthiazol-4-yl)phenyl]acetamide (6c)

Yield 75–78 %, m.p. 210–216°C. IR (KBr)νmax (cm−1): 3253 (amide N-H), 3053 (aromatic C-H), 2987 (aliphatic C-H), 1674 (amide C=O), 1585–1309 (C=C and C=N), 1228–979 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.59 (4H, t, J=5 Hz, N-CH2), 3.21 (2H, s, COCH2), 3.82 (4H, t, J=4.5 Hz, N-CH2), 6.62 (1H, t, J=4.5 Hz, Ar-H), 7.38 (2H, t, J=7.5 Hz, Ar-H), 7.77 (2H, d, J=8 Hz, Ar-H), 8.00 (2H, d, J=8 Hz, Ar-H), 8.06–8.08 (4H, m, Ar-H), 8.35 (2H, d, J=4.5 Hz, Ar-H), 9.93 (1H, s, N-H). 13C-NMR (125 MHz, DMSO-d6, ppm): δ 43.22, 52.48, 61.71, 110.08, 113.44, 119.57, 126.17, 126.52, 129.20, 129.24, 130.31, 133.02, 138.62, 154.97, 157.89, 161.20, 166.80, 168.28. For C25H24N6OS calculated: (%) C 65.77, H 5.30, N 18.41; found: (%) C 65.67, H 5.33, N 18.36. MS: m/z 457 (M + 1).


### 2.2.4. 2-[4-(2-Furoyl)piperazin-1-yl]-N-[4-(2-phenylthiazol-4-yl)phenyl]acetamide (6d)

Yield 70–72%, m.p. 144-145°C. IR (KBr)νmax (cm−1): 3215 (amide N-H), 3034 (aromatic C-H), 2975 (aliphatic C-H), 1676 (amide C=O), 1625–1308 (C=C and C=N), 1263–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.62 (4H, t, J=4.5 Hz, N-CH2), 3.22 (2H, s, COCH2), 3.75 (4H, t, J=4.5 Hz, N-CH2), 6.62-6.63 (1H, m, Ar-H), 7.03 (1H, d, J=3.5 Hz, Ar-H), 7.08 (2H, d, J=8.5 Hz, Ar-H), 7.79 (3H, m, Ar-H), 7.87 (1H, s, Ar-H), 7.97–8.05 (5H, m, Ar-H), 9.93 (1H, s, N-H). For C26H24N4O3S calculated: (%) C 66.08, H 5.12, N 11.86; found: (%) C 68.13, H 5.17, N 11.93. MS: m/z 473 (M + 1).


### 2.2.5. 2-(4-Benzylpiperazin-1-yl)-N-[4-(2-(4-methoxyphenyl)thiazol-4-yl)phenyl]acetamide (6e)

Yield 80–82%, m.p. 171–175°C. IR (KBr)νmax (cm−1): 3302 (amide N-H), 3041 (aromatic C-H), 2952 (aliphatic C-H), 1653 (amide C=O), 1587–1305 (C=C and C=N), 1244–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.46 (4H, t, J=5 Hz, N-CH2), 2.56 (4H, t, J=4.5 Hz, N-CH2), 3.14 (2H, s, COCH2), 3.48 (2H, s, C-CH2), 3.83 (3H, s, OCH3), 7.08 (2H, d, J=9 Hz, Ar-H), 7.30–7.32 (5H, m, Ar-H), 7.72 (2H, d, J=8.5 Hz, Ar-H), 7.95–7.98 (5H, m, Ar-H), 9.82 (1H, s, N-H). For C29H30N4O2S calculated: (%) C 69.85, H 6.06, N 11.24; found: (%) C 69.92, H 6.14, N 11.31. MS: m/z 499 (M + 1).


### 2.2.6. 2-[4-(Pyridin-2-yl)piperazin-1-yl]-N-[4-(2-(4-methoxyphenyl)thiazol-4-yl)phenyl]acetamide (6f)

Yield 78–80%, m.p. 153-154°C. IR (KBr)νmax (cm−1): 3317 (amide N-H), 3014 (aromatic C-H), 2941 (aliphatic C-H), 1656 (amide C=O), 1589–1303 (C=C and C=N), 1247–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.63 (4H, t, J=5 Hz, N-CH2), 3.21 (2H, s, COCH2), 3.56 (4H, t, J=4.5 Hz, N-CH2), 3.84 (3H, s, OCH3), 6.63 (1H, t, J=6 Hz, Ar-H), 6.83 (1H, d, J=8.5 Hz, Ar-H), 7.08 (2H, d, J=9 Hz, Ar-H), 7.52 (1H, t, J=5 Hz, Ar-H), 7.76 (2H, d, J=8.5 Hz, Ar-H), 7.95–7.99 (5H, m, Ar-H), 8.11 (1H, d, J=5 Hz, Ar-H), 9.90 (1H, s, N-H). For C27H27N5O2S calculated: (%) C 66.78, H 5.60, N 14.42; found: (%) C 66.85, H 5.68, N 14.50. MS: m/z 486 (M + 1).


### 2.2.7. 2-[4-(Pyrimidin-2-yl)piperazin-1-yl]-N-[4-(2-(4-methoxyphenyl)thiazol-4-yl)phenyl]acetamide (6g)

Yield 78–80%, m.p. 160–163°C. IR (KBr)νmax (cm−1): 3315 (amide N-H), 3038 (aromatic C-H), 2951 (aliphatic C-H), 1676 (amide C=O), 1596–1307 (C=C and C=N), 1261–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.59 (4H, t, J=5 Hz, N-CH2), 3.21 (2H, s, COCH2), 3.81 (4H, t, J=5 Hz, N-CH2), 3.83 (3H, s, OCH3), 6.63 (1H, t, J=4.5 Hz, Ar-H), 7.08 (2H, d, J=9 Hz, Ar-H), 7.76 (2H, d, J=9 Hz, Ar-H), 7.95-7.96 (5H, m, Ar-H), 8.36 (2H, d, J=5 Hz, Ar-H), 9.91 (1H, s, N-H). For C26H26N6O2S calculated: (%) C 64.18, H 5.39, N 17.27; found: (%) C 64.25, H 5.44, N 17.32. MS: m/z 487 (M + 1).


### 2.2.8. 2-[4-(2-Furoyl)piperazin-1-yl]-N-[4-(2-(4-methoxyphenyl)thiazol-4-yl)phenyl]acetamide (6h)

Yield 74–76%, m.p. 136–138°C. IR (KBr)νmax (cm−1): 3279 (amide N-H), 3063 (aromatic C-H), 2927 (aliphatic C-H), 1658 (amide C=O), 1604–1306 (C=C and C=N), 1236–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.61 (4H, t, J=5 Hz, N-CH2), 3.24 (2H, s, COCH2), 3.76 (4H, t, J=5 Hz, N-CH2), 3.87 (3H, s, OCH3), 6.63-6.64 (1H, m, Ar-H), 7.01 (1H, d, J=3.5 Hz, Ar-H), 7.08 (2H, d, J=9 Hz, Ar-H), 7.77 (2H, d, J=8.5 Hz, Ar-H), 7.85 (1H, s, Ar-H), 7.96–8.01 (5H, m, Ar-H), 9.94 (1H, s, N-H). 13C-NMR (125 MHz, DMSO-d6, ppm): δ 53.18, 53.55, 55.87, 61.82, 111.76, 112.85, 115.06, 115.40, 115.99, 120.08, 126.37, 126.96, 128.25, 129.84, 139.00, 145.15, 147.48, 155.17, 158.79, 161.41, 167.21, 168.66. For C27H26N4O4S calculated: (%) C 64.52, H 5.21, N 11.15; found: (%) C 64.46, H 5.29, N 11.24. MS: m/z 503 (M + 1).


### 2.2.9. 2-(4-Benzylpiperazin-1-yl)-N-[4-(2-(4-chlorophenyl)thiazol-4-yl)phenyl]acetamide (6i)

Yield 70–73%, m.p. 171–173°C. IR (KBr)νmax (cm−1): 3288 (amide N-H), 3013 (aromatic C-H), 2966 (aliphatic C-H), 1664 (amide C=O), 1591–1315 (C=C and C=N), 1234–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.50 (4H, brs, N-CH2), 3.14 (2H, s, COCH2), 3.48 (2H, s, C-CH2), 7.08 (2H, d, J=9 Hz, Ar-H), 7.29–7.32 (5H, m, Ar-H), 7.60 (2H, d, J=8.5 Hz, Ar-H), 7.75 (2H, d, J=8.5 Hz, Ar-H), 7.97 (1H, d, J=8.5 Hz, Ar-H), 8.04 (1H, d, J=8.5 Hz, Ar-H), 8.11 (1H, s, Ar-H), 9.82 (1H, s, N-H). For C28H27ClN4OS calculated: (%) C 66.85, H 5.41, N 11.14; found: (%) C 66.94, H 5.47, N 11.20. MS: m/z 502.5 (M + 1).


### 2.2.10. 2-[4-(Pyridin-2-yl)piperazin-1-yl]-N-[4-(2-(4-chlorophenyl)thiazol-4-yl)phenyl]acetamide (6j)

Yield 73–76%, m.p. 220–225°C. IR (KBr)νmax (cm−1): 3300 (amide N-H), 3002 (aromatic C-H), 2924 (aliphatic C-H), 1666 (amide C=O), 1591–1305 (C=C and C=N), 1244–1018 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.63 (4H, t, J=4.5 Hz, N-CH2), 3.22 (2H, s, COCH2), 3.56 (4H, t, J=4.5 Hz, N-CH2), 6.63–6.65 (1H, m, Ar-H), 6.83 (1H, d, J=8.5 Hz, Ar-H), 7.53 (1H, t, J=4.5 Hz, Ar-H), 7.60 (2H, d, J=8.5 Hz, Ar-H), 7.78 (2H, d, J=8.5 Hz, Ar-H), 8.03 (2H, d, J=8.5 Hz, Ar-H), 8.06 (2H, d, J=8.5 Hz, Ar-H), 8.12 (2H, s, Ar-H), 9.92 (1H, s, N-H). 13C-NMR (125 MHz, DMSO-d6, ppm): δ 45.05, 52.98, 62.25, 107.58, 113.45, 114.44, 120.06, 127.05, 128.37, 129.53, 129.81, 132.34, 135.33, 137.98, 139.19, 148.04, 155.60, 159.51, 165.95, 168.80. For C26H24ClN5OS calculated: (%) C 63.73, H 4.94, N 14.29; found: (%) C 63.81, H 4.98, N 14.32. MS: m/z 489.5 (M + 1).


### 2.2.11. 2-[4-(Pyrimidin-2-yl)piperazin-1-yl]-N-[4-(2-(4-chlorophenyl)thiazol-4-yl)phenyl]acetamide (6k)

Yield 70–74%, m.p. 196–198°C. IR (KBr)νmax (cm−1): 3290 (amide N-H), 3022 (aromatic C-H), 2931 (aliphatic C-H), 1670 (amide C=O), 1585–1309 (C=C and C=N), 1256–979 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.59 (4H, t, J=4.5 Hz, N-CH2), 3.21 (2H, s, COCH2), 3.81 (4H, t, J=4.5 Hz, N-CH2), 6.62 (1H, t, J=5 Hz, Ar-H), 7.59 (2H, d, J=8.5 Hz, Ar-H), 7.77 (2H, d, J=8.5 Hz, Ar-H), 8.02 (2H, d, J=8.5 Hz, Ar-H), 8.05 (2H, d, J=8.5 Hz, Ar-H), 8.12 (1H, s, Ar-H), 8.35 (2H, d, J=4.5 Hz, Ar-H), 9.92 (1H, s, N-H). For C25H23ClN6OS calculated: (%) C 61.15, H 4.72, N 17.12; found: (%) C 61.23, H 4.80, N 17.16. MS: m/z 490.5 (M + 1).


### 2.2.12. 2-[4-(2-Furoyl)piperazin-1-yl]-N-[4-(2-(4-chlorophenyl)thiazol-4-yl)phenyl]acetamide (6l)

Yield 72–75%, m.p. 139–141°C. IR (KBr)νmax (cm−1): 3317 (amide N-H), 3042 (aromatic C-H), 2962 (aliphatic C-H), 1676 (amide C=O), 1625–1305 (C=C and C=N), 1261–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.60 (4H, t, J=5 Hz, N-CH2), 3.34 (2H, s, COCH2), 3.74 (4H, t, J=5 Hz, N-CH2), 6.62-6.63 (1H, m, Ar-H), 7.01 (1H, d, J=3.5 Hz, Ar-H), 7.59 (2H, d, J=8.5 Hz, Ar-H), 7.76–7.83 (2H, m, Ar-H), 7.95–8.15 (6H, s, Ar-H), 9.96 (1H, s, N-H). For C26H23ClN4O3S calculated: (%) C 61.59, H 4.57, N 11.05; found: (%) C 61.65, H 4.63, N 11.12. MS: m/z 506.5 (M + 1).


### 2.2.13. 2-(4-Benzylpiperazin-1-yl)-N-[4-(2-(4-florophenyl)thiazol-4-yl)phenyl]acetamide (6m)

Yield 69–73%, m.p. 171-172°C. IR (KBr)νmax (cm−1): 3317 (amide N-H), 3015 (aromatic C-H), 2970 (aliphatic C-H), 1678 (amide C=O), 1502–1306 (C=C and C=N), 1234–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.45 (4H, t, J=5 Hz, N-CH2), 2.54 (4H, t, J=4.5 Hz, N-CH2), 3.14 (2H, s, COCH2), 3.48 (2H, s, C-CH2), 7.24–7.39 (7H, m, Ar-H), 7.73 (2H, d, J=8.5 Hz, Ar-H), 7.99 (2H, d, J=8.5 Hz, Ar-H), 8.06–8.11 (3H, m, Ar-H), 9.85 (1H, s, N-H). For C28H27FN4OS calculated: (%) C 69.11, H 5.59, N 11.51; found: (%) C 69.18, H 5.65, N 11.63. MS: m/z 487 (M + 1).


### 2.2.14. 2-[4-(Pyridin-2-yl)piperazin-1-yl]-N-[4-(2-(4-florophenyl)thiazol-4-yl)phenyl]acetamide (6n)

Yield 70–74%, m.p. 163-164°C. IR (KBr)νmax (cm−1): 3317 (amide N-H), 3023 (aromatic C-H), 2987 (aliphatic C-H), 1678 (amide C=O), 1591–1305 (C=C and C=N), 1247–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.63 (4H, t, J=4.5 Hz, N-CH2), 3.22 (2H, s, COCH2), 3.56 (4H, t, J=5 Hz, N-CH2), 6.62–6.65 (1H, m, Ar-H), 6.83 (1H, d, J=8.5 Hz, Ar-H), 7.35–7.39 (2H, m, Ar-H), 7.53 (1H, t, J=4.5 Hz, Ar-H), 7.76 (2H, d, J=8.5 Hz, Ar-H), 7.99 (2H, d, J=8.5 Hz, Ar-H), 8.06–8.12 (4H, m, Ar-H), 9.91 (1H, s, N-H). For C26H24FN5OS calculated: (%) C 65.94, H 5.11, N 14.79; found: (%) C 65.86, H 5.18, N 14.65. MS: m/z 474 (M + 1).


### 2.2.15. 2-[4-(Pyrimidin-2-yl)piperazin-1-yl]-N-[4-(2-(4-florophenyl)thiazol-4-yl)phenyl]acetamide (6o)

Yield 70–74%, m.p. 187-188°C. IR (KBr)νmax (cm−1): 3317 (amide N-H), 3036 (aromatic C-H), 2954 (aliphatic C-H), 1677 (amide C=O), 1583-1307 (C=C and C=N), 1257–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.61 (4H, t, J=3 Hz, N-CH2), 3.22 (2H, s, COCH2), 3.83 (4H, t, J=4.5 Hz, N-CH2), 6.63 (1H, t, J=4.5 Hz, Ar-H), 7.50–7.56 (3H, m, Ar-H), 7.78 (2H, d, J=9 Hz, Ar-H), 7.98–8.06 (4H, m, Ar-H), 8.09 (1H, s, Ar-H), 8.37 (2H, d, J=8.5 Hz, Ar-H), 9.93 (1H, s, N-H). 13C-NMR (125 MHz, DMSO-d6, ppm): δ 43.71, 52.97, 62.19, 110.59, 114.03, 116.68, 116.85, 120.07, 127.02, 128.95, 129.02, 129.62, 130.19, 139.14, 155.44, 158.40, 161.70, 162.74, 166.13, 168.80. For C25H23FN6OS calculated: (%) C 63.27, H 4.89, N 17.71; found: (%) C 63.19, H 4.94, N 17.66. MS: m/z 475 (M + 1).


### 2.2.16. 2-[4-(2-Furoyl)piperazin-1-yl]-N-[4-(2-(4-florophenyl)thiazol-4-yl)phenyl]acetamide (6p)

Yield 74–78%, m.p. 146–148°C. IR (KBr)νmax (cm−1): 3319 (amide N-H), 3031 (aromatic C-H), 2927 (aliphatic C-H), 1674 (amide C=O), 1589–1307 (C=C and C=N), 1232–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.60 (4H, t, J=5 Hz, N-CH2), 3.34 (2H, s, COCH2), 3.74 (4H, t, J=5 Hz, N-CH2), 6.61–6.62 (1H, m, Ar-H), 7.03 (1H, d, J=3.5 Hz, Ar-H), 7.61 (2H, d, J=8.5 Hz, Ar-H), 7.75–7.80 (2H, m, Ar-H), 7.98–8.16 (6H, s, Ar-H), 9.92 (1H, s, N-H). For C26H23FN4O3S calculated: (%) C 63.66, H 4.73, N 11.42; found: (%) C 63.72, H 4.81, N 11.46. MS: m/z 491 (M + 1).


## 2.2.1.2-(4-Benzylpiperazin-1-yl)-N-[4-(2-phenylthiazol-4-yl)phenyl]acetamide (6a)

Yield 70–76%, m.p. 171–174°C. IR (KBr)νmax (cm−1): 3281 (amide N-H), 3005 (aromatic C-H), 2912 (aliphatic C-H), 1676 (amide C=O), 1512–1306 (C=C and C=N), 1190–978 (C-O and C-N). 1H-NMR (125 MHz, DMSO-d6, ppm): δ 2.45 (4H, t, J=5 Hz, N-CH2), 2.55 (4H, t, J=4.5Hz, N-CH2), 3.15 (2H, s, COCH2), 3.49 (2H, s, C-CH2), 7.25–7.35 (5H, m, Ar-H), 7.51–7.56 (3H, m, Ar-H), 7.75 (2H, d, J=9 Hz, Ar-H), 7.99-8.04 (4H, m, Ar-H), 8.09 (1H, s, Ar-H), 9.82 (1H, s, N-H). 13C-NMR (500 MHz, DMSO-d6, ppm): δ 52.45, 52.80, 61.81, 62.04, 113.44, 119.49, 126.17, 126.53, 126.87, 128.14, 128.79, 129.17, 129.25, 130.32, 133.01, 138.22, 138.58, 154.96, 166.81, 168.35. For C28H28N4OS calculated: (%) C 71.76, H 6.02, N 11.96; found: (%) C 71.71, H 6.10, N 11.91. MS: m/z 469 (M + 1).


## 2.2.2. 2-[4-(Pyridin-2-yl)piperazin-1-yl]-N-[4-(2-phenylthiazol-4-yl)phenyl]acetamide (6b)

Yield 70–76 %, m.p. 173–176°C. IR (KBr)νmax (cm−1): 3319 (amide N-H), 3091 (aromatic C-H), 2912 (aliphatic C-H), 1676 (amide C=O), 1524–1309 (C=C and C=N), 1246–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.61 (4H, t, J=5 Hz, N-CH2), 3.23 (2H, s, COCH2), 3.76 (4H, brs, N-CH2), 6.63-6.64 (1H, m, Ar-H), 6.99-7.00 (1H, m, Ar-H), 7.52–7.56 (4H, m, Ar-H), 7.76 (2H, d, J=9 Hz, Ar-H), 7.84–7.85 (1H, m, Ar-H), 8.00–8.09 (5H, m, Ar-H), 9.92 (1H, s, N-H). For C26H25N5OS calculated: (%) C 68.55, H 5.53, N 15.37; found: (%) C 68.62, H 5.63, N 15.40. MS: m/z 456 (M + 1).


## 2.2.3. 2-[4-(Pyrimidin-2-yl)piperazin-1-yl]-N-[4-(2-phenylthiazol-4-yl)phenyl]acetamide (6c)

Yield 75–78 %, m.p. 210–216°C. IR (KBr)νmax (cm−1): 3253 (amide N-H), 3053 (aromatic C-H), 2987 (aliphatic C-H), 1674 (amide C=O), 1585–1309 (C=C and C=N), 1228–979 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.59 (4H, t, J=5 Hz, N-CH2), 3.21 (2H, s, COCH2), 3.82 (4H, t, J=4.5 Hz, N-CH2), 6.62 (1H, t, J=4.5 Hz, Ar-H), 7.38 (2H, t, J=7.5 Hz, Ar-H), 7.77 (2H, d, J=8 Hz, Ar-H), 8.00 (2H, d, J=8 Hz, Ar-H), 8.06–8.08 (4H, m, Ar-H), 8.35 (2H, d, J=4.5 Hz, Ar-H), 9.93 (1H, s, N-H). 13C-NMR (125 MHz, DMSO-d6, ppm): δ 43.22, 52.48, 61.71, 110.08, 113.44, 119.57, 126.17, 126.52, 129.20, 129.24, 130.31, 133.02, 138.62, 154.97, 157.89, 161.20, 166.80, 168.28. For C25H24N6OS calculated: (%) C 65.77, H 5.30, N 18.41; found: (%) C 65.67, H 5.33, N 18.36. MS: m/z 457 (M + 1).


## 2.2.4. 2-[4-(2-Furoyl)piperazin-1-yl]-N-[4-(2-phenylthiazol-4-yl)phenyl]acetamide (6d)

Yield 70–72%, m.p. 144-145°C. IR (KBr)νmax (cm−1): 3215 (amide N-H), 3034 (aromatic C-H), 2975 (aliphatic C-H), 1676 (amide C=O), 1625–1308 (C=C and C=N), 1263–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.62 (4H, t, J=4.5 Hz, N-CH2), 3.22 (2H, s, COCH2), 3.75 (4H, t, J=4.5 Hz, N-CH2), 6.62-6.63 (1H, m, Ar-H), 7.03 (1H, d, J=3.5 Hz, Ar-H), 7.08 (2H, d, J=8.5 Hz, Ar-H), 7.79 (3H, m, Ar-H), 7.87 (1H, s, Ar-H), 7.97–8.05 (5H, m, Ar-H), 9.93 (1H, s, N-H). For C26H24N4O3S calculated: (%) C 66.08, H 5.12, N 11.86; found: (%) C 68.13, H 5.17, N 11.93. MS: m/z 473 (M + 1).


## 2.2.5. 2-(4-Benzylpiperazin-1-yl)-N-[4-(2-(4-methoxyphenyl)thiazol-4-yl)phenyl]acetamide (6e)

Yield 80–82%, m.p. 171–175°C. IR (KBr)νmax (cm−1): 3302 (amide N-H), 3041 (aromatic C-H), 2952 (aliphatic C-H), 1653 (amide C=O), 1587–1305 (C=C and C=N), 1244–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.46 (4H, t, J=5 Hz, N-CH2), 2.56 (4H, t, J=4.5 Hz, N-CH2), 3.14 (2H, s, COCH2), 3.48 (2H, s, C-CH2), 3.83 (3H, s, OCH3), 7.08 (2H, d, J=9 Hz, Ar-H), 7.30–7.32 (5H, m, Ar-H), 7.72 (2H, d, J=8.5 Hz, Ar-H), 7.95–7.98 (5H, m, Ar-H), 9.82 (1H, s, N-H). For C29H30N4O2S calculated: (%) C 69.85, H 6.06, N 11.24; found: (%) C 69.92, H 6.14, N 11.31. MS: m/z 499 (M + 1).


## 2.2.6. 2-[4-(Pyridin-2-yl)piperazin-1-yl]-N-[4-(2-(4-methoxyphenyl)thiazol-4-yl)phenyl]acetamide (6f)

Yield 78–80%, m.p. 153-154°C. IR (KBr)νmax (cm−1): 3317 (amide N-H), 3014 (aromatic C-H), 2941 (aliphatic C-H), 1656 (amide C=O), 1589–1303 (C=C and C=N), 1247–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.63 (4H, t, J=5 Hz, N-CH2), 3.21 (2H, s, COCH2), 3.56 (4H, t, J=4.5 Hz, N-CH2), 3.84 (3H, s, OCH3), 6.63 (1H, t, J=6 Hz, Ar-H), 6.83 (1H, d, J=8.5 Hz, Ar-H), 7.08 (2H, d, J=9 Hz, Ar-H), 7.52 (1H, t, J=5 Hz, Ar-H), 7.76 (2H, d, J=8.5 Hz, Ar-H), 7.95–7.99 (5H, m, Ar-H), 8.11 (1H, d, J=5 Hz, Ar-H), 9.90 (1H, s, N-H). For C27H27N5O2S calculated: (%) C 66.78, H 5.60, N 14.42; found: (%) C 66.85, H 5.68, N 14.50. MS: m/z 486 (M + 1).


## 2.2.7. 2-[4-(Pyrimidin-2-yl)piperazin-1-yl]-N-[4-(2-(4-methoxyphenyl)thiazol-4-yl)phenyl]acetamide (6g)

Yield 78–80%, m.p. 160–163°C. IR (KBr)νmax (cm−1): 3315 (amide N-H), 3038 (aromatic C-H), 2951 (aliphatic C-H), 1676 (amide C=O), 1596–1307 (C=C and C=N), 1261–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.59 (4H, t, J=5 Hz, N-CH2), 3.21 (2H, s, COCH2), 3.81 (4H, t, J=5 Hz, N-CH2), 3.83 (3H, s, OCH3), 6.63 (1H, t, J=4.5 Hz, Ar-H), 7.08 (2H, d, J=9 Hz, Ar-H), 7.76 (2H, d, J=9 Hz, Ar-H), 7.95-7.96 (5H, m, Ar-H), 8.36 (2H, d, J=5 Hz, Ar-H), 9.91 (1H, s, N-H). For C26H26N6O2S calculated: (%) C 64.18, H 5.39, N 17.27; found: (%) C 64.25, H 5.44, N 17.32. MS: m/z 487 (M + 1).


## 2.2.8. 2-[4-(2-Furoyl)piperazin-1-yl]-N-[4-(2-(4-methoxyphenyl)thiazol-4-yl)phenyl]acetamide (6h)

Yield 74–76%, m.p. 136–138°C. IR (KBr)νmax (cm−1): 3279 (amide N-H), 3063 (aromatic C-H), 2927 (aliphatic C-H), 1658 (amide C=O), 1604–1306 (C=C and C=N), 1236–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.61 (4H, t, J=5 Hz, N-CH2), 3.24 (2H, s, COCH2), 3.76 (4H, t, J=5 Hz, N-CH2), 3.87 (3H, s, OCH3), 6.63-6.64 (1H, m, Ar-H), 7.01 (1H, d, J=3.5 Hz, Ar-H), 7.08 (2H, d, J=9 Hz, Ar-H), 7.77 (2H, d, J=8.5 Hz, Ar-H), 7.85 (1H, s, Ar-H), 7.96–8.01 (5H, m, Ar-H), 9.94 (1H, s, N-H). 13C-NMR (125 MHz, DMSO-d6, ppm): δ 53.18, 53.55, 55.87, 61.82, 111.76, 112.85, 115.06, 115.40, 115.99, 120.08, 126.37, 126.96, 128.25, 129.84, 139.00, 145.15, 147.48, 155.17, 158.79, 161.41, 167.21, 168.66. For C27H26N4O4S calculated: (%) C 64.52, H 5.21, N 11.15; found: (%) C 64.46, H 5.29, N 11.24. MS: m/z 503 (M + 1).


## 2.2.9. 2-(4-Benzylpiperazin-1-yl)-N-[4-(2-(4-chlorophenyl)thiazol-4-yl)phenyl]acetamide (6i)

Yield 70–73%, m.p. 171–173°C. IR (KBr)νmax (cm−1): 3288 (amide N-H), 3013 (aromatic C-H), 2966 (aliphatic C-H), 1664 (amide C=O), 1591–1315 (C=C and C=N), 1234–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.50 (4H, brs, N-CH2), 3.14 (2H, s, COCH2), 3.48 (2H, s, C-CH2), 7.08 (2H, d, J=9 Hz, Ar-H), 7.29–7.32 (5H, m, Ar-H), 7.60 (2H, d, J=8.5 Hz, Ar-H), 7.75 (2H, d, J=8.5 Hz, Ar-H), 7.97 (1H, d, J=8.5 Hz, Ar-H), 8.04 (1H, d, J=8.5 Hz, Ar-H), 8.11 (1H, s, Ar-H), 9.82 (1H, s, N-H). For C28H27ClN4OS calculated: (%) C 66.85, H 5.41, N 11.14; found: (%) C 66.94, H 5.47, N 11.20. MS: m/z 502.5 (M + 1).


## 2.2.10. 2-[4-(Pyridin-2-yl)piperazin-1-yl]-N-[4-(2-(4-chlorophenyl)thiazol-4-yl)phenyl]acetamide (6j)

Yield 73–76%, m.p. 220–225°C. IR (KBr)νmax (cm−1): 3300 (amide N-H), 3002 (aromatic C-H), 2924 (aliphatic C-H), 1666 (amide C=O), 1591–1305 (C=C and C=N), 1244–1018 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.63 (4H, t, J=4.5 Hz, N-CH2), 3.22 (2H, s, COCH2), 3.56 (4H, t, J=4.5 Hz, N-CH2), 6.63–6.65 (1H, m, Ar-H), 6.83 (1H, d, J=8.5 Hz, Ar-H), 7.53 (1H, t, J=4.5 Hz, Ar-H), 7.60 (2H, d, J=8.5 Hz, Ar-H), 7.78 (2H, d, J=8.5 Hz, Ar-H), 8.03 (2H, d, J=8.5 Hz, Ar-H), 8.06 (2H, d, J=8.5 Hz, Ar-H), 8.12 (2H, s, Ar-H), 9.92 (1H, s, N-H). 13C-NMR (125 MHz, DMSO-d6, ppm): δ 45.05, 52.98, 62.25, 107.58, 113.45, 114.44, 120.06, 127.05, 128.37, 129.53, 129.81, 132.34, 135.33, 137.98, 139.19, 148.04, 155.60, 159.51, 165.95, 168.80. For C26H24ClN5OS calculated: (%) C 63.73, H 4.94, N 14.29; found: (%) C 63.81, H 4.98, N 14.32. MS: m/z 489.5 (M + 1).


## 2.2.11. 2-[4-(Pyrimidin-2-yl)piperazin-1-yl]-N-[4-(2-(4-chlorophenyl)thiazol-4-yl)phenyl]acetamide (6k)

Yield 70–74%, m.p. 196–198°C. IR (KBr)νmax (cm−1): 3290 (amide N-H), 3022 (aromatic C-H), 2931 (aliphatic C-H), 1670 (amide C=O), 1585–1309 (C=C and C=N), 1256–979 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.59 (4H, t, J=4.5 Hz, N-CH2), 3.21 (2H, s, COCH2), 3.81 (4H, t, J=4.5 Hz, N-CH2), 6.62 (1H, t, J=5 Hz, Ar-H), 7.59 (2H, d, J=8.5 Hz, Ar-H), 7.77 (2H, d, J=8.5 Hz, Ar-H), 8.02 (2H, d, J=8.5 Hz, Ar-H), 8.05 (2H, d, J=8.5 Hz, Ar-H), 8.12 (1H, s, Ar-H), 8.35 (2H, d, J=4.5 Hz, Ar-H), 9.92 (1H, s, N-H). For C25H23ClN6OS calculated: (%) C 61.15, H 4.72, N 17.12; found: (%) C 61.23, H 4.80, N 17.16. MS: m/z 490.5 (M + 1).


## 2.2.12. 2-[4-(2-Furoyl)piperazin-1-yl]-N-[4-(2-(4-chlorophenyl)thiazol-4-yl)phenyl]acetamide (6l)

Yield 72–75%, m.p. 139–141°C. IR (KBr)νmax (cm−1): 3317 (amide N-H), 3042 (aromatic C-H), 2962 (aliphatic C-H), 1676 (amide C=O), 1625–1305 (C=C and C=N), 1261–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.60 (4H, t, J=5 Hz, N-CH2), 3.34 (2H, s, COCH2), 3.74 (4H, t, J=5 Hz, N-CH2), 6.62-6.63 (1H, m, Ar-H), 7.01 (1H, d, J=3.5 Hz, Ar-H), 7.59 (2H, d, J=8.5 Hz, Ar-H), 7.76–7.83 (2H, m, Ar-H), 7.95–8.15 (6H, s, Ar-H), 9.96 (1H, s, N-H). For C26H23ClN4O3S calculated: (%) C 61.59, H 4.57, N 11.05; found: (%) C 61.65, H 4.63, N 11.12. MS: m/z 506.5 (M + 1).


## 2.2.13. 2-(4-Benzylpiperazin-1-yl)-N-[4-(2-(4-florophenyl)thiazol-4-yl)phenyl]acetamide (6m)

Yield 69–73%, m.p. 171-172°C. IR (KBr)νmax (cm−1): 3317 (amide N-H), 3015 (aromatic C-H), 2970 (aliphatic C-H), 1678 (amide C=O), 1502–1306 (C=C and C=N), 1234–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.45 (4H, t, J=5 Hz, N-CH2), 2.54 (4H, t, J=4.5 Hz, N-CH2), 3.14 (2H, s, COCH2), 3.48 (2H, s, C-CH2), 7.24–7.39 (7H, m, Ar-H), 7.73 (2H, d, J=8.5 Hz, Ar-H), 7.99 (2H, d, J=8.5 Hz, Ar-H), 8.06–8.11 (3H, m, Ar-H), 9.85 (1H, s, N-H). For C28H27FN4OS calculated: (%) C 69.11, H 5.59, N 11.51; found: (%) C 69.18, H 5.65, N 11.63. MS: m/z 487 (M + 1).


## 2.2.14. 2-[4-(Pyridin-2-yl)piperazin-1-yl]-N-[4-(2-(4-florophenyl)thiazol-4-yl)phenyl]acetamide (6n)

Yield 70–74%, m.p. 163-164°C. IR (KBr)νmax (cm−1): 3317 (amide N-H), 3023 (aromatic C-H), 2987 (aliphatic C-H), 1678 (amide C=O), 1591–1305 (C=C and C=N), 1247–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.63 (4H, t, J=4.5 Hz, N-CH2), 3.22 (2H, s, COCH2), 3.56 (4H, t, J=5 Hz, N-CH2), 6.62–6.65 (1H, m, Ar-H), 6.83 (1H, d, J=8.5 Hz, Ar-H), 7.35–7.39 (2H, m, Ar-H), 7.53 (1H, t, J=4.5 Hz, Ar-H), 7.76 (2H, d, J=8.5 Hz, Ar-H), 7.99 (2H, d, J=8.5 Hz, Ar-H), 8.06–8.12 (4H, m, Ar-H), 9.91 (1H, s, N-H). For C26H24FN5OS calculated: (%) C 65.94, H 5.11, N 14.79; found: (%) C 65.86, H 5.18, N 14.65. MS: m/z 474 (M + 1).


## 2.2.15. 2-[4-(Pyrimidin-2-yl)piperazin-1-yl]-N-[4-(2-(4-florophenyl)thiazol-4-yl)phenyl]acetamide (6o)

Yield 70–74%, m.p. 187-188°C. IR (KBr)νmax (cm−1): 3317 (amide N-H), 3036 (aromatic C-H), 2954 (aliphatic C-H), 1677 (amide C=O), 1583-1307 (C=C and C=N), 1257–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.61 (4H, t, J=3 Hz, N-CH2), 3.22 (2H, s, COCH2), 3.83 (4H, t, J=4.5 Hz, N-CH2), 6.63 (1H, t, J=4.5 Hz, Ar-H), 7.50–7.56 (3H, m, Ar-H), 7.78 (2H, d, J=9 Hz, Ar-H), 7.98–8.06 (4H, m, Ar-H), 8.09 (1H, s, Ar-H), 8.37 (2H, d, J=8.5 Hz, Ar-H), 9.93 (1H, s, N-H). 13C-NMR (125 MHz, DMSO-d6, ppm): δ 43.71, 52.97, 62.19, 110.59, 114.03, 116.68, 116.85, 120.07, 127.02, 128.95, 129.02, 129.62, 130.19, 139.14, 155.44, 158.40, 161.70, 162.74, 166.13, 168.80. For C25H23FN6OS calculated: (%) C 63.27, H 4.89, N 17.71; found: (%) C 63.19, H 4.94, N 17.66. MS: m/z 475 (M + 1).


## 2.2.16. 2-[4-(2-Furoyl)piperazin-1-yl]-N-[4-(2-(4-florophenyl)thiazol-4-yl)phenyl]acetamide (6p)

Yield 74–78%, m.p. 146–148°C. IR (KBr)νmax (cm−1): 3319 (amide N-H), 3031 (aromatic C-H), 2927 (aliphatic C-H), 1674 (amide C=O), 1589–1307 (C=C and C=N), 1232–978 (C-O and C-N). 1H-NMR (500 MHz, DMSO-d6, ppm): δ 2.60 (4H, t, J=5 Hz, N-CH2), 3.34 (2H, s, COCH2), 3.74 (4H, t, J=5 Hz, N-CH2), 6.61–6.62 (1H, m, Ar-H), 7.03 (1H, d, J=3.5 Hz, Ar-H), 7.61 (2H, d, J=8.5 Hz, Ar-H), 7.75–7.80 (2H, m, Ar-H), 7.98–8.16 (6H, s, Ar-H), 9.92 (1H, s, N-H). For C26H23FN4O3S calculated: (%) C 63.66, H 4.73, N 11.42; found: (%) C 63.72, H 4.81, N 11.46. MS: m/z 491 (M + 1).


## 2.3. Antimicrobial Activity

The study was designed to compare MICs obtained by the CLSI reference M7–A7 broth microdilution method [15]. MIC readings were performed twice for each chemical agent. Final products were tested for theirin vitro growth inhibitory activity against human pathogenic microorganisms as Gram-positive bacteria,Enterococcus faecalis (ATCC 29212) and as Gram-negative bacteria,Pseudomonas aeruginosa (ATCC 27853),Klebsiella pneumoniae (ATCC 700603),Escherichia coli (ATCC 35218), andE. coli (ATCC 25922) and yeast asCandida albicans(90028),Candida glabrata (ATCC 90030),Candida krusei (ATCC 6258), andCandida parapsilosis (ATCC 7330). Chloramphenicol and ketoconazole were used as control drugs.


## 2.4. Anticholinesterase Activity

The inhibition of acetylcholinesterase enzyme, AChE (E.C.3.1.1.7 from Electric Eel, 500 units), was determined spectrophotometrically using acetylthiocholine (ATC) as substrate according to the modified method of Ellman’s test [16]. Enzyme solutions were prepared in gelatin solution (1%), at a concentration of 2.5 units/mL. AChE and compound solution (50 µL) which is prepared in 2% dimethyl sulfoxide at 0.1 and 1 mM concentrations were added to 3.0 mL phosphate buffer (pH 8 ± 0.1) and incubated at 25°C for 5 min. The reaction was started by adding 5,5-dithio-bis(2-nitrobenzoic)acid, DTNB (50 µL), and ATC (10 µL) to the enzyme-inhibitor mixture. Spectrophotometric measurements were performed on a 1700 Shimadzu UV-1700 UV–Vis spectrophotometer at 412 nm. Donepezil hydrochloride was used as a positive control and all processes were assayed in triplicate [17].


## 3. Results and Discussion

The final compounds (6a–6n) were synthesized by a five-step (Figure 1), convenient synthetic routeaccording to the literaturereported before [14]. Different 4-substituted thiobenzamides (H, OCH3, Cl, F) were used as starting materials. They have reacted withN-[4-(2-bromoacetyl)phenyl]acetamide to obtain thiazole compounds (3). After deacetylation of these intermediates, 2-chloro-N-[4-(2-(4-substituted phenyl)-4-thiazolyl)phenyl]acetamides (5) were gained with chloroacetyl chloride. Finally, 2-[4-(aryl)piperazin-1-yl]-N-[4-(2-(4-substituted phenyl)thiazol-4-yl)phenyl]acetamide derivatives (6a–6n) were afforded by the reaction of compound5 and corresponding piperazine derivatives. Synthetic protocol for the compounds is outlined in Figure 1. Structure elucidations of the final compounds were performed with IR, 1H NMR, and MS spectroscopic methods. In the IR spectra of the final compounds, characteristic stretching bands were observed at 3253–3319 cm−1 for N-H bond, 1303–1625 cm−1 for C=C and C=N bonds, 978–1263 cm−1 for C-N and C-O bonds, and 1653–1678 cm−1 for C=O bond, respectively. In the NMR spectra of the compounds6a–6n, protons of piperazine CH2 were observed at about 2.50–2.63 ppm and 3.56–3.82 ppm ranges as triplets or broad singlets. The protons bonded to carbonyl were assigned at 3.14–3.34 ppm and heterocyclic rings and chloro/fluoro substituted phenyl rings were given peaks near to downfield region. Aromatic protons resonated at a large area between 6.62 and 8.37 ppm and amide protons were determined at about 9.82–9.96 ppm, as singlet peaks. Regarding to the mass spectra, all final compounds exhibited similar behavior in their fragmentation pattern, showing the molecular ion peak.Figure 1
Synthesis of the compounds(6a–6p). Reagents are (i) acetyl chloride, TEA, THF, 0–5°C; (ii) Br2, AcOH; (iii) thiobenzamide derivatives, EtOH, r.t.; (iv) 10 % HCl, EtOH, reflux; (v) chloroacetyl chloride, TEA, THF, r.t.; and (vi) appropriate 4-substituted piperazine derivatives, K2CO3, acetone, reflux.All final compounds were screened for their acetylcholinesterase inhibitory activities and antimicrobial activities. Initially, 2-(4-arylpiperazine-1-yl)-N-[4-(2-(4-substituted phenyl)thiazol-4-yl)phenyl]acetamide derivatives (6a–6p) have been designed and synthesizedfor investigation of their potential anticholinesterase activity. According to our previous study [14], 2-(4-substituted piperazine-1-yl)-N-[4-(2-methylthiazol-4-yl)phenyl]acetamide derivatives based on the structure of AChE inhibitors donepezil, BYYT-25 and acotiamide were investigated and compounds with pyridyl, benzyl, and furoyl piperazine substituents were observed with high anticholinesterase activity. This study was planned to improve new anticholinesterase compounds using the same skeleton, but with different substitutions. However, in contrast to expectations the synthesized compounds (6a–6n) did not show any noticeable anticholinesterase activity (Table 2). It is evident that phenyl/4-substituted phenyl moiety at the second position of thiazole ring has eliminated activity. Only two compounds6j and6mhave exhibited inhibition over 50% at the highest tested dose (1 mM).Whereupon considering many studies on thiazole derivatives biological profile, we tend to screen antimicrobial activity of the synthesized 2,4-disubstituted thiazole compounds. Sixteen new compounds were tested for their antibacterial and antifungal activities. The antifungal activity of the compounds was found to be higher than their antimicrobial activities (Table1). Compounds6c and6d showed higher activity than the other compounds againstE. faecaliswhich is a Gram-positive bacterium. Among the tested Gram-negative bacteria, compounds6c–6f,6i and6j exhibited the highest activity againstK. pneumoniawith a MIC value of 100 µg/mL which is two-fold standard drug’s MIC value. Compound6l showed equipotent activity to standard drug againstanother Gram-negative bacteriumP. aeruginosa. Against two testedE. colispecies (ATCC 35218 and ATCC 25922), only compounds6d and6m displayed moderate antibacterial activity compared with standard drug chloramphenicol. As for the antifungal activity, compounds showed higher activities against four testedCandida species. Compounds6a,6b,6i, and6m exhibited same efficiency with ketoconazole againstC. albicans and also compound6f towardsC. glabrata. AgainstC. krusei, the MIC value was found as 50 µg/mL for compound6a which was very high according to ketoconazole’s MIC value (3.13 µg/mL). Among allCandida species, the most sensitiveCandida was established asC. parapsilosis. Compounds6b,6c, and6h were found twice as active as standard drug, whereas compounds6a,6d,6e,6f,6m, and6n showed equipotent activity. All the other compounds displayed half the potency of ketoconazole against the same microorganism.Table 1
Antimicrobial activity of the compounds6a–6p (MIC, µg/mL).
Comp.
A
B
C
D
E
F
G
H
I
6a
200
200
200
200
200
50
100
50
100
6b
200
200
200
200
200
50
100
100
50
6c
100
100
200
200
200
200
100
200
50
6d
100
100
200
200
100
200
100
100
100
6e
200
100
200
200
400
200
100
100
100
6f
200
100
100
200
200
100
50
100
100
6g
200
100
100
200
200
100
100
100
200
6h
200
200
200
400
200
200
100
100
50
6i
200
100
200
200
400
50
100
100
200
6j
200
100
200
200
400
100
200
200
200
6k
200
200
100
200
400
100
200
200
200
6l
200
200
50
200
200
100
200
200
200
6m
200
200
200
200
100
50
100
100
100
6n
200
200
200
200
200
200
200
200
100
6o
200
200
200
200
200
100
200
200
200
6p
200
200
200
200
200
200
200
800
200
Ref. 1
25
50
50
25
25
—
—
—
—
Ref. 2
—
—
—
—
—
50
50
3.13
100
Reference 1: Chloramphenicol, Reference 2: Ketoconazole.
A:E. faecalis (ATCC 29212), B: K. pneumonia (ATCC 700603), C: P. aeruginosa (ATCC 27853), D: E. coli (ATCC 35218), E: E. coli (ATCC 25922), F: C. albicans (ATCC 90028), G: C. glabrata (ATCC 90030), H: C. krusei (ATCC 6258), I: C. parapsilosis (ATCC 7330).Table 2
% AChE inbition of the compounds6a–6p and IC50 values.
Compounds
% AChE Inhibition
IC50 (mM)
1 mM
0.1 mM
6a
3.45 ± 5.10
—
6b
7.19 ± 8.45
—
6c
—
—
6d
—
—
6e
10.16 ± 10.12
—
6f
2.86 ± 2.15
—
6g
2.03 ± 3.21
—
6h
7.28 ± 4.69
—
6i
8.63 ± 3.25
—
6j
57.04 ± 10.65
17.09 ± 2.3
0.84 ± 5.36
6k
37.09 ± 5.16
27.78 ± 5.12
6l
29.59 ± 11.23
5.39 ± 2.11
6m
58.79 ± 5.61
49.65 ± 6.49
0.13 ± 3.74
6n
43.96 ± 5.84
40.58 ± 5.89
6o
41.96 ± 6.89
40.52 ± 7.36
6p
44.68 ± 2.68
42.92 ± 3.55
Donepezil
98.24 ± 1.87
92.23 ± 2.62
0.054 ± 0.002 (µM)
ND: Not determined.p<0.01 (unpaired Student’s t test between test compound and Donepezil).The structures of the tested compounds were based on a thiazole ring which has phenyl moiety at second and fourth positions of it. The substitutions of the phenyl ring at second position are methoxy, chloro and fluoro groups. The difference at the fourth position of the thiazole ring is pyridyl, pyrimidinyl benzyl, and furoyl piperazine moieties bonded to phenyl ring with an amide linker. 2-Furoyl piperazine substitution has attracted attention for its antibacterial activity. In antifungal activity evaluation, nonsubstituted phenyl group and different substituted piperazine substitutions were observed with significant activity according toCandidaspecies.


## 4. Conclusion

Sixteen new 2-(4-substituted phenyl)-4-(acetamidophenyl)thiazole including compounds were synthesized. All final compounds were screened for their antibacterial, antifungal, and anticholinesterase activities. None of the compounds showed prominent anticholinesterase activity. Antifungal activity of the compounds was found promising. Compounds6b,6c, and6h exhibited two-fold anticandidal activity compared with ketoconazole againstC. parapsilosis.



---

*Source: 464379-2015-06-22.xml*